Clinical Trials Browser

Phase 2 × INDUSTRY × Tyrosine Kinase Inhibitors × Clear all

NCT07219459 2025-10-21

GDFATHERHCC01

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03890731 2024-04-02

A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed

Phase 2 Completed

6 enrolled 11 charts

GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms